Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review

QR Code

Paritaprevir/ritonavir-ombitasvir and dasabuvir, the 3D regimen for the treatment of chronic hepatitis C virus infection: a concise review

Trana Hussaini1,2 1Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada; 2Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, BC, Canada Abstract: The treatment for chronic hepatitis C has been revolutionized with the development of direct-acting ant...

Description complète

Enregistré dans:

Détails bibliographiques
Auteur principal:	Hussaini T
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2016
Sujets:	Hepatitis C Paritaprevir Ombitasvir Dasabuvir 3D Regimen Diseases of the digestive system. Gastroenterology RC799-869
Accès en ligne:	https://doaj.org/article/5db086ab4bc344cea8a7abd9d0ae81d0
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
par: Bernstein D, et autres
Publié: (2019)

Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain
par: Abdulla MA, et autres
Publié: (2017)

Hepatitis C in the Russian Federation: challenges and future directions
par: Mukomolov S, et autres
Publié: (2016)

Expert opinion on the management of hepatitis C infection in Kuwait
par: Saad MF, et autres
Publié: (2018)

Challenging hepatitis C-infected liver transplant patients
par: Oliver M, et autres
Publié: (2016)

Hepatitis C in Lebanon: the burden of the disease and the value of comprehensive screening and treatment
par: Abou Rached A, et autres
Publié: (2018)

Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies
par: Mendes LC, et autres
Publié: (2018)

Efficacy of Ombitasvir/Paritaprevir/Ritonavir plus Ribavirin in Treatment of Chronic Hepatitis C Patients with End Stage Renal Disease on Regular Hemodialysis
par: Naglaa El-Gendy, et autres
Publié: (2020)

Hepatitis C infection in Egypt: prevalence, impact and management strategies
par: Gomaa A, et autres
Publié: (2017)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
par: Naylor PH, et autres
Publié: (2017)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
par: Pol S, et autres
Publié: (2016)

Hepatic sarcoidosis: Clinical characteristics and outcome
par: Christiana Graf, et autres
Publié: (2021)

Rifaximin in the treatment of hepatic encephalopathy
par: Iadevaia MD, et autres
Publié: (2011)

Epidemiology and treatment of autoimmune hepatitis
par: Francque S, et autres
Publié: (2012)

Hepatitis C in Argentina: epidemiology and treatment
par: Gaite LA, et autres
Publié: (2014)

Evolving concepts in the selection of immunosuppression regimen for liver transplant recipients
par: Locke JE, et autres
Publié: (2011)

Transmission, diagnosis, and management of hepatitis E: an update
par: Mirazo S, et autres
Publié: (2014)

Update on entecavir in the management of severe forms of Hepatitis B
par: Sacco R
Publié: (2012)

Reversal of hepatic fibrosis: pathophysiological basis of antifibrotic therapies
par: Ismail MH, et autres
Publié: (2011)

Ending hepatitis C in the United States: the role of screening
par: Coffin PO, et autres
Publié: (2014)

Decline in HAV-associated fulminant hepatic failure and liver transplant in children in Argentina after the introduction of a universal hepatitis A vaccination program
par: Cervio G, et autres
Publié: (2011)

The role of eltrombopag in the management of hepatitis C virus-related thrombocytopenia
par: Danish FA, et autres
Publié: (2013)

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
par: Roggeri DP, et autres
Publié: (2015)

A high prevalence of extreme hyperferritinemia in acute hepatitis patients
par: Kazuhiro Kotoh, et autres
Publié: (2009)

Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent
par: JIANG Jun
Publié: (2021)

Novel drugs in the management of difficult-to-treat hepatitis C genotypes
par: Cartwright EJ, et autres
Publié: (2013)

Interferon-free combination therapies for the treatment of hepatitis C: current insights
par: Holmes JA, et autres
Publié: (2015)

Hepatitis C infection in Egypt: prevalence, impact and management strategies [Corrigendum]
par: Gomaa A, et autres
Publié: (2017)

Percutaneous hepatic radiofrequency for hepatocellular carcinoma: results and outcome of 46 patients
par: Bertr, et autres
Publié: (2015)

Risk Prediction of Nosocomial and Posthospital Discharge Infections in Alcohol‐Associated Hepatitis
par: Daniel D. Penrice, et autres
Publié: (2021)

A case of hepatic portal venous gas due to viral gastroenteritis
par: Mirmanesh M, et autres
Publié: (2013)

Efficacy of bowel preparation regimens for colon capsule endoscopy: a systematic review and meta-analysis
par: Thomas Bjoersum-Meyer, et autres
Publié: (2021)

Sofosbuvir for the treatment of chronic hepatitis C: between current evidence and future perspectives
par: Degasperi E, et autres
Publié: (2014)

Clinical features and prognosis of primary myelofibrosis with hepatic vascular disease and/or portal hypertension
par: WANG Jing
Publié: (2021)

Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated
par: JIANG Yingying
Publié: (2021)

Clinical applications of the Model for End-Stage Liver Disease (MELD) in hepatic medicine
par: Lau T, et autres
Publié: (2013)

Association between hepatic fat and subclinical vascular disease burden in the general population
par: Susanne Rospleszcz, et autres
Publié: (2021)

Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes
par: Page K, et autres
Publié: (2019)

New-onset ascites as a manifestation of virologic relapse in patients with hepatitis C cirrhosis
par: Chua DL, et autres
Publié: (2014)

Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus
par: Bruno S, et autres
Publié: (2011)